Clinical Trials Arena May 24, 2024
Robert Barrie

Shares in the pharma company rose 40% in pre-market trading.

Verastem Oncology reported positive initial results from an ongoing Phase I/II trial investigating kinase inhibitor avutometinib for the treatment of pancreatic cancer.

The US biopharma company announced the initial interim safety and efficacy results as it gears up for a presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting on 1 June 2024.

Verastem’s trial, named RAMP 205, is a single-arm study evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel, the latter two being standard-of-care chemotherapy, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Out of the six patients receiving 2.4mg avutometinib, five achieved a confirmed overall response rate (ORR). The 83% ORR exceeds...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Roche partners with RNA editing biotech Ascidian
340B drug program spending up 19% + 6 other notes
Healthy Returns: More U.S. employers are now covering GLP-1s for weight loss
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
Amazon Pharmacy Targets Medicare Population

Share This Article